← Eichor
Condition: Growth Factor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Growth Factor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT04836156Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Gl
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06059690Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Phase 1/Phase 2 · 12 location(s) · Artios Pharma Ltd · NCT05898399Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2-
Phase 3 · 1 location(s) · Genentech, Inc. · NCT07541079Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surge
Phase 2 · 4 location(s) · University of Chicago · NCT06348134Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy
Phase 3 · 18 location(s) · Dompé Farmaceutici S.p.A · NCT07453888Open, Non-comparative Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Plasma Rich in Growth Factors (PRG
NA · 1 location(s) · Instituto de Investigación Sanitaria de la Fundación Jiménez · NCT06975683Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Phase N/A · 1 location(s) · Cedars-Sinai Medical Center · NCT02910180A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activat
Phase 1 · 15 location(s) · Jazz Pharmaceuticals · NCT05557045Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients
Phase N/A · 1 location(s) · Antonio Bellasi · NCT06668831PIERS and BIS, sFIT:PIGF, Adrenomedullin
Phase N/A · 1 location(s) · Suez Canal University · NCT02578810A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Phase 2 · 3 location(s) · Yale University · NCT02491099Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Phase 3 · 1 location(s) · Queen Mary Hospital, Hong Kong · NCT06643416Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Canc
Phase 1/Phase 2 · 1 location(s) · Guangzhou Medical University · NCT06462092A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2 · 3 location(s) · Anwaar Saeed · NCT06698250JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT07111520NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Phase 2 · 8 location(s) · Swiss Cancer Institute · NCT06452394Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06830551MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Phase 1/Phase 2 · 3 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT06712875TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05901428Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07546695A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G
Phase N/A · 1 location(s) · Eisai Co., Ltd. · NCT06793709Right Ventricular Function Changes After CIED Implantation: The RIGHT-CIED Study
Phase N/A · 1 location(s) · Istanbul University - Cerrahpasa · NCT07272395
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.